I WANT to emphasize that I am not against the use of anticoagulants, fundamentally. My "against" implies opposition to an uncritical use of these drugs. The main purpose of my lecture is to show that we do not yet know enough about the value of anticoagulant therapy.
To begin with, I want to talk about the treatment of myocardial infarctions in the acute stage. Nearly everybody will agree today that a favorable effect on the coronary arterial thrombosis is most unlikely. What we can gain is a certain reduction of the secondary thromboembolic complications, nrst of all of the pulmonary emboli. Consequently, the treatment is similar to the use of anticoagulants in many other circumstances, such as postoperative cases, patients with fractures, etc.
In this relation I want to show you the frequency of thromboembolic complications in acute myocardial infarctions from various epochs. In series of untreated cases you will see that this frequency is steadily decreasing from 1948 until now (table 1) . Today the frequency is around 10 to 15 per cent, which is not much more than that observed in the treated groups.
It seems likely to me that the reason for this decrease in spontaneous thromboembolism is the increasing mobilization of patients with acute myocardial infarction. There has been a gradual change in the regime used in these patients.
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prophylaxis against thrombus formation in the coronary arteries themselves. Many papers have been published on this topic, but only five include comparable control groups.8 7 A certain tendency to reduction of the rates of reinfarction and mortality appears in these five studies. But when we look at the different series, we find very conflicting results. In some papers the protective effect of the long-term treatment is mainly seen in patients below the age of 60, in other papers mainly in the older age groups. Some authors consider the treatment of importance only in the first year, but one author held the treatment to be valuable during the second to fourth year, especially (table 2) . In a study from Copenhagen we found no over-all reduction, neither in the re-infarction rate nor in the mortality rate. In our publication in 1962 we stated that the effect, if any, of long-term anticoagulant therapy is so slight that in small series it is not at all manifest or only in subgroups, now in one, now in another. 7 Most of you will be familiar with a study of ence could be seen (table 5) . From these experiences we got the impression that longterm treatment might be of value in patients with less advanced coronary artery disease.
From this point of view we considered the results from other long-term studies. In Bjerkelund's material from Norway, a very careful study, the protective effect was equal- No angina pectoris, no previous infarcts, no symptoms of cardiac incompensation, no diabetes mellitus, age below 65 years. Table 4 The Table 6 The What we have to do is, I think, to wait for or to try to establish further experiences from well-controlled materials.
